Drugs / Cord blood stem cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03885947 | Feb 2019 → Mar 2021 | Hodgkins lymphoma, acute lymphoblastic leukemia, myelodysplastic syndrome | Alla Keyzner | Completed | No outcome recorded |
| Phase 1 | NCT01019681 | Nov 2009 → Jan 2014 | limb ischemia | Richard Burt, MD | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00539656 | Dec 2007 → Oct 2009 | acute lymphoblastic leukemia, chronic myeloid leukemia, mixed phenotype acute leukemia | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04040127 | Sep 2019 → Jan 2020 | pulpitis | University of California, San Francisco | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cord blood stem cells | “Transplantations utilizing umbilical cord blood stem cells are increasingly successful.” NCT00539656 ↗3“The cord blood stem cells will be simply injected intramuscularly in the leg.” NCT01019681 ↗ |
| Known as | InvitRx | “The experiments outlined in this proposal are designed to test the hypothesis that the in vivo injection of cord blood stem cells (InvitRx®) into the root canal system will...” NCT04040127 ↗ |
| Modality | Cell therapy | “Cord blood stem cell injection” NCT01019681 ↗ |
| Route | Intramuscular | “injected intramuscularly in the leg” NCT01019681 ↗ |